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A key event for Ras transformation involves the direct
physical association between Ras and the Raf-l kinase.
This interaction promotes both Raf translocation to the
plasma membrane and activation ofRaf kinase activity.
Although substantial experimental evidence has demon-
strated that Raf residues 51-131 alone are sufficient for
Ras binding, conflicting observations have suggested
that the Raf cysteine-rich domain (residues 139-184)
may also be important for interaction with Ras. To clar-
ify the role of the Raf eysteine-rteh domain in Ras-Raf
binding, we have compared the ability of two distinct
Raf fragments to interact with Ras using both in vitro
Ras binding and in vivo Ras inhibition assays. First, we
determined that both Raf sequences 2-140 and 139-186
(designated Raf-Cys) showed preferential binding to ac-
tive, GTP-bound Ras in vitro. Second, we observed that
Raf-Cys antagonized oncogenic Ras(Q61L)-mediated
transactivation of Ras-responsive elements and focus-
forming activity in NIH 3T3 cells and insulin-induced
germinal vesicle breakdown in Xenopus loeois oocytes
in vivo. This inhibitory activity suggests that Raf-Cys
can interact with Ras in vivo. Taken together, these
results suggest that Ras interaction with two distinct
domains of Raf-l may be important in Bas-mediated ac-
tivation of Raf kinase activity.
Numerous biochemical and genetic studies have positioned
Raf downstream of Ras in Ras-dependent signal transduction
pathways (1) that lead to the activation of the mitogen-acti-
vated protein kinases (2). Furthermore, several recent investi-
gations have used in vitro protein binding assays and the in
vivo yeast two-hybrid system to demonstrate a direct physical
association between the Ras and Raf proteins, thus identifying
Raf as a key downstream target, or effector, of Ras-mediated
signal transduction (3-8). This interaction requires the effector
domain of Ras (residues 32-40) and a region in the amino-
terminal regulatory domain of Raf. The region encompassing
Raf-1 amino acids 51-131 has been shown to be sufficient for
interaction with Ras (6, 9, 10). In addition, a single amino acid
mutation (R89L) in this domain of Raf disrupts the interaction
with Ras in vitro and prevents Ras-mediated activation of Raf
in sm insect cells (11).
While Raf residues 51-131 clearly define a minimal Ras
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binding domain, other evidence has suggested that the Raf
cysteine-rich domain (residues 139-184) may also be involved
in Ras-Raf binding. First, a single point mutation (C168S) in
this domain was found to reduce Raf(residues 1-257) binding
to Ras in both two-hybrid and in vitro binding assays (5).
Second, it was observed that renaturation of Raf-(1-257) in the
presence of zinc, which is required for folding of the cysteine-
rich domain, led to greater restoration of Ras binding activity
(4). Finally, we and others observed that Rafresidues 131-147,
which are adjacent to and extend partially into the cysteine-
rich domain, are critically important for conferring high affin-
ity binding to Ras in vitro (9, 10). However, it remains to be
clarified whether the Raf cysteine-rich domain enhances Ras
association with Raf residues 51-131 or independently inter-
acts with Ras. To address this question, we have utilized both
in vitro and in vivo analyses to characterize Ras interaction
with the Raf cysteine-rich domain. We observe that the isolated
Raf cysteine-rich domain shows high affinity, guanine nucle-
otide-dependent binding to Ras in vitro and can function as a
dominant inhibitor ofRas signaling and transformation in vivo.
Thus, the Raf NH2 terminus contains two distinct Ras binding
domains that may be important for Ras-mediated activation of
Raf kinase activity.
EXPERIMENTAL PROCEDURES
Molecular Constructs-To generate mammalian expression vector
constructs encoding different Raffragments, we isolated BamHI-EcoRI
DNA fragments from pGEX-raf constructs that encoded the different
Raf sequences indicated in Fig. 1 (12) and introduced each into the
BamHI site of the pCGN-hyg mammalian expression vector (13) (gen-
erously provided by M. Ostrowski, Duke). Raf301 encodes a full-length
mutant human Raf-1 sequence that contains a single amino acid sub-
stitution (K to W) in the ATP binding site, which inactivates its kinase
activity (14).
Expression and Purification of Ras and Glutathione Ss'Iransferase-
Raf Proteins-The pAT-rasH bacterial expression plasmid and proce-
dures for expression and purification have been described previously
(15). Ras protein complexed to GMPPCP,' a nonhydrolyzable GTP
analog (Boehringer Mannheim), was prepared as described elsewhere
(16) by replacement of GDP bound to Ras. Glutathione S-transferase-
Raf proteins were purified as described previously (12).
Enzyme-linked Immunosorbent Assay (ELISA) for Measuring Ras-
RafInteraction in Vitro-Purified glutathione S-transferase and gluta-
thione S-transferase-Raf proteins were plated onto 96-well microtiter
plates (Costar) coated with 0.025 mg/ml poly-L-lysine and allowed to
bind overnight. Wells were blocked for 1 h at room temperature with a
phosphate-buffered saline solution containing 130 mM NaCl, 10 mM
Na2HP04 , and 3 mM KCl, pH 7.40 (PBS), which was supplemented with
0.5%gelatin, 0.05% Tween 20, and 0.2% sheep serum (PBSGTS). H-Ras
complexed to either GDP or GMPPCP was captured in PBSGTS for 1 h
at concentrations ranging from 31 nM to 2 JLM. The plates were washed
'The abbreviations used are: GMPPCP, guanosine 5'-(I3,y-methyl-
enetriphosphate); CAT, chloramphenicol acetyltransferase; ELISA, en-
zyme-linked immunosorbent assay; MEK, mitogen-activated protein
kinase/extracellular signal-regulated kinase kinase.
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FIG. 1. Molecular constructs of Raf-l. The amino acid residues
encoded by the various human Raf constructs are indicated as well as
the locations of the Raf cysteine-rich and kinase domains. The pGEX-
raf bacterial expression and pCGN-raf mammalian expression con-

































FIG. 2. The Ras cysteine-rich domain preferentially binds to
Ras-GTP. Three distinct Raf fragments, prepared as glutathione S-
transferase-Raf fusion proteins, were tested for their ability to bind
Ras-GDP and Ras-GMPPCP by antigen capture ELISA as described
under "Experimental Procedures." Both Raf-N2 and Raf-Cys exhibited
preferential binding to Ras-"GTP," whereas Raf-C did not bind to either
form of Ras. Raf-N2 and Raf-Cys bound to Ras-GTPwith 130 and 48 nM
C50 values compared with 870 and 310 nM for Ras-GDP, respectively.
All experiments were performed in triplicate with glutathione S-trans-
ferase (control) absorbance values subtracted from the absorbance
values of glutathione S-transferase-Raf proteins.
both fragments showed -7-fold preferential binding to Ras-
GTP relative to Ras-GDP. Therefore, these results indicate
that two distinct regions within the NH2-terminal regulatory
domain of Raf-1 are capable of specific interaction with GTP-
Ras in vitro.
Two Independent Amino-terminal Domains ofRafBlock On-
cogenic Ras Signaling and Transformation in Vivo-Previous
studies have yielded discrepancies between the ability of dif-
ferent Ras and Rafmutants to bind when performed by in vitro
versus in vivo two-hybrid analyses (21). Therefore, we em-
ployed three biological assays to determine if Ras-Cys could
associate with Ras in vivo and consequently block Ras signal-
ing and transforming activity. We and others have previously
shown that kinase-deficient mutants of Raf can block Ras func-
tion by antagonizing Ras interaction with its downstream ef-
fectors (14, 22, 23). Thus, an inhibitory activity of a Rafmutant
RESULTS AND DISCUSSION
The RafCysteine-rich Domain Shows High Affinity, GTP-de-
pendent Association with Ras in Vitro-Although extensive
analyses have clearly shown that Raf residues 51-131 alone
are sufficient for interaction with Ras, it is presently unclear
what the precise role of the cysteine-rich domain (residues
139-184) is in mediating Ras-Raf binding. To address the
possibility that this domain can bind Ras, we have conducted
both ELISA and direct binding assays (12) to determine if
Raf-Cys binds directly to Ras in vitro and to assess the depend-
ence of this association on the guanine nucleotide-bound state
of Ras. For these assays, we compared the binding activities of
a glutathione S-transferase fusion protein containing Raf-Cys
with the binding properties of glutathione S-transferase-Raf-
(2-140) (designated Raf-N2), which contains the minimal Raf
sequence required for Ras binding (51-131) and includes only
the first two residues from the cysteine-rich domain (Fig. 1).
Fig. 2 shows data obtained from an ELISA using various
purified recombinant glutathione S-transferase-Raf fragments
and Ras. For these experiments we prepared stoichiometric
complexes of Ras bound to GMPPCP. This non hydrolyzable
GTP analog eliminates GTP hydrolysis during the course ofthe
experiment and is useful for determining whether various Raf
fragments bind to Ras in a GTP-dependent fashion. Binding
curves were generated by serially diluting Ras complexed to
either GMPPCP or GDP into wells containing 100 pmol of each
glutathione S-transferase-Raf protein. We observed that both
Raf-Cys and Raf-N2 showed high affinity binding to Ras. In
contrast, a Raf fragment lacking the NHz-terminal regulatory
domain (containing Raf residues 273-648; designated Raf-C)
did not bind to Ras. Furthermore, the concentration depend-
ence of the binding curves demonstrates that much higher
concentrations of Ras-GDP relative to Ras-GMPPCP were re-
quired to saturate binding to either Raf-N2 or Raf-Cys, and
3 times in PBS with 0.1% Tween 20 and then incubated for 1 h with an
anti-H-Ras antibody (LA069) (Quality Biotech) diluted 2000-fold in
PBSGTS. The wash step was repeated, and the plates were incubated
with a 1:1000 dilution of sheep anti-mouse IgG-alkaline phosphatase
conjugate (Sigma) in PBSGTS for 30 min, followed by development with
the chromogen, p-nitrophenyl phosphate (Sigma). Optical densities
(405 nm) were read after 30 min in a Biotech microtiter plate reader.
The intensity of the absorbance was directly related to the amount of
Ras bound. The concentration of Ras at half-maximal binding was
determined as described previously (12).
NIH 3T3 Transcription Activation and Transformation Assays-NIH
3T3 cells were grown in Dulbecco's modified Eagle's medium supple-
mented with 10% calf serum. DNA transfections were performed as
described previously using the calcium phosphate precipitation tech-
nique (17). The pB4X-CAT reporter plasmid contains the CAT gene, and
CAT is driven by a minimal promoter that contains the ets/AP-1 Ras-
responsive promoter element (18). Cells were co-transfected with the
pZIP-rasH(Q61L) plasmid DNA encoding H-Ras(Q61L) (50 rig/dish) and
either the empty pCGN-hyg vector or the appropriate pCGN-raf con-
struct (5 jLg/dish) along with 1 jLg of the pB4X-CAT reporter. Forty-
eight h after transfection, total cell lysates were prepared, and CAT
activity was determined as described previously (19). A similar co-
transfection analysis was done to assess the ability of each Raf mutant
(5 jLg/dish) to block Ras(Q61L) (10 ng/dish) transforming activity.
Transfections were performed in triplicate, and transformed foci were
quantitated after 14-16 days.
Preparation and Experimental Manipulation of Oocytes-Oocytes
were isolated from primed Xenopus laevis ovaries by procedures de-
scribed previously (20). Isolated stage VI oocytes were injected with 200
J.tg of the indicated glutathione S-transferase-Raf protein (20 oocytes/
Raf protein) in a volume of 40 nL Subsequent to the injection, the
oocytes were treated with 1 J.tM insulin and maintained in modified
Barth's solution with Ca 2 + , between 18 and 20°C, for maturation.
Insulin-induced maturation was scored at definite time intervals by
counting the number of oocytes undergoing germinal vesicle breakdown
manifested by the appearance of a whitish spot at the pigmented
animal pole of the oocytes.
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FIG. 3. Multiple, independent do-
mains ofRaf-l inhibit Ras-dependent
signaling in vivo. Panel A, Raf frag-
ments block Ras(Q61L) stimulation of
transcriptional activation of the ets/AP-l
Ras-responsive element. Results from one
of four experiments performed in dupli-
cate are shown. CAT assays were per-
formed as described under "Experimental
Procedures." Panel B, co-transfection of
various Raf fragments significantly re-
duces Ras(Q61L) focus-forming activity.
Two experiments were performed in trip-
licate, and results of one are presented.
Relative focus-forming units (FFU) shown
are normalized to the activity of
Ras(Q61L) (8.97 X 103 foci/f.Lg of trans-
fected DNA). Panel C, stage VI oocytes
from X. laevis were isolated and injected
with 200 ~ each of the indicated pro-
teins. The oocytes were then treated with
insulin and scored for germinal vesicle
breakdown (GVBD), as described under
"Experimental Procedures." The data are
presented as the percent of oocytes under-
going germinal vesicle breakdown as a
function of time after treatment with in-
sulin (compare 15-h time point). GST, glu-
tathione S-transferase.
is a strong indication of an in vivo interaction with Ras that
prevents Ras association with full-length, endogenous Ras ef-
fectors. We included the well characterized, kinase-deficient
Ram01 dominant inhibitory protein as a control for these
studies (14).
We first evaluated the ability of each Raf-1 fragment to
inhibit oncogenic Ras-mediated stimulation of transcription
from a Ras-responsive reporter plasmid (Fig. 3A). As shown
previously (22, 23), Ram01 reduced Ras-induced transcrip-
tional activation, whereas wild type Raffurther stimulated Ras
transcriptional activation (data not shown). Additionally, we
observed that both Raf-Cys and Raf-N1 reduced activation by
oncogenic Ras in vivo. Furthermore, Raf constructs containing
both the minimal Ras binding sequence (residues 51-131) and
sequences from the cysteine-rich domain (residues 139-184)
showed the strongest inhibition oftranscriptional activity, pos-
sibly due to the cooperative binding of the two independent
binding sites.
We next determined whether Raf-Cys could also inhibit on-
cogenic Ras(Q61L) focus-forming activity. Co-transfection of
Raf-Cys as well as other Raffragments that contained overlap-
ping sequences showed >50% inhibition of oncogenic
Ras(Q61L) focus-forming activity (Fig. 3R). One possible expla-
nation for the inhibitory action of these Raf fragments is that
they inhibit cell growth in a nonspecific manner. However, we
observed that for NIH 3T3 cells transfected with each raf
construct, equivalent numbers of hygromycin-resistant colo-
nies are obtained following drug selection of cells transfected
with vector only or with vector constructs encoding each of the
Raf fragments (data not shown), thus arguing against this
possibility. Additionally, we have isolated stably transfected
cells that co-express both oncogenic Ras(Q61L) and certain Raf
fragments, and these cells show a flatter morphology, which is
more characteristic of untransformed NIH 3T3 cells (data not
shown).
Finally, we observed that Raf-Cys and Raf-Cys+ could
block insulin-induced germinal vesicle breakdown in X. laevis
oocytes (Fig. 3C). Previous studies have shown that this insulin
response is dependent on Ras activity (24-26). This inhibitory
activity could be reversed by co-injection of excess oncogenic
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Ras protein (data not shown). Thus, we have observed that, like
the truncated Raf fragment containing the residues corre-
sponding to the minimal Ras binding sequence (residues 51-
131), the Raf cysteine-rich domain can inhibit oncogenic Ras
transcriptional activation, transforming activity, and oocyte
maturation. Taken together, these observations in vivo are
consistent with our demonstration that Raf-Cys can bind di-
rectly to Ras in vitro and support the possibility that Raf
contains a second distinct Ras binding site, which can promote
Ras-Raf interaction in vivo.
A Noncatalytic Carboxyl-terminal Raf Mutant Blocks Ras
Signaling in Vivo-Although Raf-C showed no Ras binding
activity in vitro (Fig. 2A), we did observe that this Raffragment
could inhibit oncogenic Ras-mediated transcription activation
(Fig. 3A), focus-forming activity (Fig. 3R), and insulin-induced
oocyte maturation (Fig. 3C). Raf-C (residues 273-648) lacks
both NHz-terminal Ras binding domains and contains the ser-
ine-threonine kinase domain (residues 333-625). However, a
previous study has demonstrated that Raf-C lacks transform-
ing activity (27). Thus, we suggest that the inhibitory activity
of Raf-C is not a consequence of complex formation with Ras
but instead that it inhibits Ras transforming activity by com-
plex formation with the Raf substrate, MEK. MEK has been
shown to bind to Raf COOH-terminal sequences that include
the kinase domain (7). Consistent with this possibility, we
found that exogenously introduced wild type MEK reversed the
inhibitory action of Raf-C but not of Raf-Nl (data not shown).
Therefore, Raf-C may function as a dominant inhibitor ofMEK
activity, thereby inhibiting signaling downstream of Ras.
Although previous studies have implicated the Raf cysteine-
rich domain in facilitating Ras binding, the precise nature of
this role was unclear. Our observations that Raf-Cys shows
high affinity, GTP-dependent binding to Ras in vitro and can
antagonize Ras function in vivo provide evidence that the cys-
teine-rich domain constitutes a second Ras binding site in the
RafNHz-terminal regulatory domain. These results provide an
explanation for the reduction in Ras binding, observed both in
vitro and in vivo, to an amino-terminal Raf fragment, Raf-(I-
257), containing a mutation (CI68S) that disrupts the integrity
of the cysteine-rich domain (5). Our finding is also consistent
with the observation that Raf NHz-terminal fragments con-
taining residues 131-147 (which includes residues 139-147 of
the Raf cysteine-rich domain) display increased affinity for
binding Ras (9, 10). A recent investigation has demonstrated
partially reduced coprecipitation and in vitro binding between
Ras and a Raf mutant lacking the cysteine-rich domain (28),
supporting our finding of two Ras binding sites in Raf.
Our observation that the cysteine-rich domain can bind Ras
can be reconciled with the report that a single amino acid
substitution at Raf residue 89 is sufficient to abolish Ras-Raf
interaction (11). While it is possible that expression of the
isolated cysteine-rich domain may have unmasked a nonspe-
cific binding activity for Ras that is not a property of full-length
Raf, our observation that this domain preferentially interacts
with the active, GTP-complexed form of Ras argues that this
interaction is specific. Instead, we propose that the Ras binding
site in the cysteine-rich domain is protected in the intact,
unstimulated protein, possibly due to negative regulatory con-
tacts with the COOH-terminal domain. We propose that Ras
may initially interact with Raf via contacts with residues be-
tween positions 51 and 131. The initial Ras-Raf interaction
and/or the resultant membrane translocation of Raf may pro-
mote exposure of the cysteine-rich domain for interaction with
Ras and possibly other activating molecules. Thus, Ras inter-
action with these two binding sequences may be necessary to
induce the removal of the negative regulatory action of the Raf
NHz terminus and consequently may facilitate Raf activation
by additional events. These may include interaction with 14-
3-3 proteins (29), tyrosine kinases (30), or lipids (12).
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